Spiropiperidine compounds as oral-1 receptor antagagonisten
申请人:Eli Lilly and Company
公开号:EP2501704B1
公开(公告)日:2013-09-18
[EN] SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS DE SPIROPIPÉRIDINE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR ORL-1
申请人:LILLY CO ELI
公开号:WO2011060217A1
公开(公告)日:2011-05-19
An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
申请人:Benito Collado Ana Belen
公开号:US20120214784A1
公开(公告)日:2012-08-23
An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.